Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
about
Coagulase-negative staphylococci.Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from AustraliaIn Vitro Antimicrobial Susceptibility of Staphylococcus pseudintermedius Isolates of Human and Animal Origin.In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studyMulticenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.Elucidating the anti-Staphylococcus aureus antibody response by immunoproteomics.Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.
P2860
Q30401758-31EE60D7-05D8-49F7-BCE3-2E75190E4242Q35169054-D5196D89-8093-4DFF-BB4B-D906D1F9E545Q35593072-CB5B994B-BCA7-4F81-BD31-940C036C8E2EQ36290502-18A5345F-9A7C-47B6-8DEC-C78479743AC4Q36834743-CE7721E2-E2B4-477C-8C3B-A385E31C7FCEQ37263425-844B496C-792A-4AE5-A9AA-94B9384F9DC7Q37613052-310CD8B6-B9FA-4C00-872A-67DBCD19235BQ38164663-50DB685B-1861-4550-AD66-965DDD04E991Q38262950-A4F0BEF2-BBA1-41B6-9D96-EEB92C6BF4D6Q38924957-19DE341B-4326-46EB-A80D-6146C3C14514Q39565510-491E9E66-0653-4CB5-9EA1-3EA424A16CD7Q40166186-487BE393-CCEF-4871-82EE-38B633C56B02Q41507443-B5034E55-F8A8-4809-816E-EFC6449E1709Q42206236-F737C6B0-6BD5-4BBA-B976-745AECDB8776
P2860
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antimicrobial activity of ceft ...... U.S. hospitals, 2008 to 2011.
@en
type
label
Antimicrobial activity of ceft ...... U.S. hospitals, 2008 to 2011.
@en
prefLabel
Antimicrobial activity of ceft ...... U.S. hospitals, 2008 to 2011.
@en
P2860
P356
P1476
Antimicrobial activity of ceft ...... U.S. hospitals, 2008 to 2011.
@en
P2093
Ronald N Jones
P2860
P304
P356
10.1128/AAC.00484-13
P407
P577
2013-04-29T00:00:00Z